Press Releases

Date Title and Summary Additional Formats
Toggle Summary AMICUS THERAPEUTICS RECEIVES U.S. ORPHAN DRUG DESIGNATION FOR AT1001 IN THE TREATMENT OF FABRY DISEASE
AMICUS THERAPEUTICS RECEIVES U.S. ORPHAN DRUG DESIGNATION FOR AT1001 IN THE TREATMENT OF FABRY DISEASE New Brunswick, NJ - Amicus Therapeutics, Inc., an emerging drug development company focused on the development of a novel therapeutic approach to the treatment of human genetic disorders, with an
View HTML
Toggle Summary AMICUS THERAPEUTICS EXPANDS INTELLECTUAL PROPERTY ESTATE
Issuance of Fourth U.S. Patent Secures Company's Proprietary Position
View HTML